Abstract
In this critical review, plant sources used as effective antibacterial agents against Helicobacter pylori infections are carefully described. The main intrinsic bioactive molecules, responsible for the observed effects are also underlined and their corresponding modes of action specifically highlighted. In addition to traditional uses as herbal remedies, in vitro and in vivo studies focusing on plant extracts and isolated bioactive compounds with anti-H. pylori activity are also critically discussed. Lastly, special attention was also given to plant extracts with urease inhibitory effects, with emphasis on involved modes of action.
1. Introduction
Plant products, their enriched-derived extracts, and their isolated bioactive molecules have been increasingly studied due their renowned health attributes, largely used in folk medicine over centuries for multiple purposes [,,,,,,,,]. Indeed, phytomedicine is garnering much attention among the medical and scientific communities [,,]. Commercially available synthetic drugs have often been negatively pointed out due to their side effects and related toxicity []. In fact, the active molecules used in pharmaceutical formulation are formerly derived from bioactive molecules extracted from plants and other living organisms []. Also, a growing number of studies have progressively underlined the multiple bioactive properties conferred by plant formulations [,]. Specifically, the antimicrobial effects of multiple plant preparations have been progressively confirmed and supported by both in vitro and in vivo studies and clinical trials [,,,,]. Thus, their lower costs, high effectiveness, bioavailability, bioefficacy, and few to no adverse effects have led to intensive research on this topic [,,,,,,].
Among the various opportunistic infections, those caused by Helicobacter pylori, a human opportunistic pathogen, is attracting much attention []. In fact, it is widely recognized that this bacterium plays an important role in the etiology of peptic and gastric ulcers and even gastric cancers and gastric lymphomas []. About half of the worldwide population is colonized by this bacterium, but there are only about 20% who manifest clinical symptoms, which has been linked to the ability of some H. pylori strains to both adapt to host’s immunological responses and to support an ever-changing gastric environment []. Relatedly, increasing rates of antibiotic-resistant H. pylori strains have been found, and therefore, the search for new eradication strategies and effective antibiotic therapies has become an issue of crucial importance []. Hence, research effort is focused on exploring plants as sources of anti-H. pylori agents.
Based on these findings, the present report aims to provide an extensive overview of Helicobacter pylori infections, namely describing its involvement in triggering gastric cancer and the most common antimicrobials used in H. pylori eradication. Special attention is also given to medicinal plants and their corresponding extracts and isolated constituents used as anti-H. pylori agents and urease inhibitors. This review was performed by consulting the databases of PubMed, Web of Science, Embase, and Google Scholar (as a search engine); only full-text available articles were considered, and articles published from 2008 to 2018 were prioritized. The search strategy included the combination of following keywords: “Helicobacter pylori”, “anti-Helicobacter”, “medicinal plant”, “plant extract”, “essential oil”, “bioactive”, “phytochemical”, “antimicrobial”, and “eradication”.
2. Helicobacter pylori and Gastric Cancer
H. pylori infection has been implicated in the development of gastric cancer, a multifactorial disease and a leading cause of mortality. The risk factors for gastric cancer have been shown to include environmental factors and factors that influence host–pathogen interaction, as well as the complex interplay between these factors []. Modern lifestyle, high stress levels, smoking and excessive alcohol consumption, nutritional deficiencies, and prolonged use of non-steroidal anti-inflammatory drugs (NSAIDs) are amongst the most relevant etiological environmental factors [].
This bacterial infection has been linked to the initiation of chronic gastritis that could later lead to adenocarcinoma of the intestine []. However, several mechanisms have been proposed to represent the involvement of H. pylori infection in tumorigenesis. Several bacterial virulence factors, such as the cytotoxin-associated gene A (CagA) protein, present in the DNA insertion element Cag pathogenicity island (CagPAI), were found to be of prominent importance in carcinogenesis []. Likewise, bacterial peptidoglycan can be delivered into gastric epithelial cells, where it activates a phosphoinositide 3-kinase (PI3K)-Akt pathway leading to cell proliferation, migration, and prevention of apoptosis []. Furthermore, H. pylori-induced gastric inflammation involves the cyclooxygenase-2 (COX2)/prostaglandin E2 (PGE2) pathway and inflammatory marker interleukin 1β (IL-1β), which are important factors triggering chronic active gastritis and adenocarcinoma []. Studies have also shown that H. pylori infection-induced oxidative stress and DNA damage coupled with dysregulation of E-cadherin/β-catenin/p120 interactions also play critical roles in tumorigenesis []. Several environmental and dietary factors have also been suggested to modify H. pylori-induced adenocarcinoma []. Gastric adenocarcinoma is strongly influenced by dietary salt intake, with high salt intake aggravating tumorigenesis [].
3. Antimicrobials for H. pylori Eradication
The success of H. pylori eradication markedly depends on the type and duration of treatment, patient compliance to therapy, and antibiotic resistance. For example, because it is difficult to achieve optimal eradication of H. pylori infection in patients with peptic ulcers, combinational regimens using two or three antibiotics in addition to a proton pump inhibitor or bismuth are often prescribed to achieve higher eradication rates and to prevent antibiotic resistance emergence [,]. These regimens, also known as triple therapies, have cure rates of around 85–90%. They are usually administered for a period of about 10–14 days, in which treatment regimens include the following: (A) bismuth subsalicylate, metronidazole, and tetracycline for 14 days; (B) omeprazole, amoxicillin, and clarithromycin for 10 days; and (C) lansoprazole, amoxicillin, and clarithromycin for either 10 or 14 days.
Unfortunately, the heightening of antimicrobial resistance has been associated with increases in the standard triple therapies failure to eradicate H. pylori infection []. Hence, research is focusing on developing potent and effective antibacterial regimens that will favor total eradication of the infection. Nonetheless, any eradication treatment comes with some degree of adverse effects, such as nausea, metallic taste, vomiting, skin rash, and diarrhea. Therefore, efforts are being channeled towards the development of effective treatments with few to no side effects.
In the Maastricht V/Florence Consensus Report, 43 experts from 24 countries provided recommendations on the basis of the best available evidence and relevance to the current therapeutic options of management of H. pylori infection in the various clinical scenarios [].
4. Plant Extracts and Phytochemicals with Anti-Helicobacter pylori Activity
Considering that H. pylori infection has been associated with gastrointestinal diseases, including chronic gastritis, peptic ulcer, gastric carcinoma, and mucosa-associated lymphoid tissue lymphoma [], and that, due to the widespread use of therapeutic agents for the eradication of this bacterium and associated-side effects, increasing rates of H. pylori strains with acquired resistance have been discovered. So, the urgent need for alternative has been rekindled and aided by the use of natural drugs [].
Despite, the newly proposed and used tri-therapy regimens, the cost of acid suppressors and stomach protectors make it inaccessible to the majority of the population []. Naturally-derived drugs, including herbs, have been shown to display anti-H. pylori activities with minimal side effects, easy accessibility, and affordability [,]. In fact, many medicinal plants have been reported in the traditional management of gastrointestinal disorders. Many of these medicinal plants have gone through bioassays to assess their potency against H. pylori. Here, the anti-H. pylori activity of medicinal plants and isolated bioactive molecules is discussed [].
Almost all plant parts have been tested for anti-H. pylori activity. Plant extract preparations include water (Table 1), essential oils (Table 2), or organic solvents, such as the following: ethanol (Table 3); methanol (Table 4); acetone (Table 5); chloroform (Table 6); petroleum ether (Table 7); methanol/water, ethanol/water, methanol/petroleum, and methanol/dichloromethane extracts (Table 8); and other plant extracts (Table 9).
Table 1.
Plant aqueous extracts with anti-Helicobacter pylori activity.
Table 2.
Plant essential oils with anti-H. pylori activity.
Table 3.
Plant ethanolic extracts with anti-H. pylori activity.
Table 4.
Plant methanolic extracts with anti-H. pylori activity.
Table 5.
Plant acetone extracts with anti-H. pylori activity.
Table 6.
Plant chloroform extracts with anti-H. pylori activity.
Table 7.
Plant petroleum ether extracts with anti-H. pylori activity.
Table 8.
Plant methanol/water, ethanol/water, methanol/petroleum, and methanol/dichloromethane extracts with anti-H. pylori activity.
Table 9.
Plant cyclohexane, dichloromethane, ethyl acetate, n-Butanol, n-Hexane, and other extracts with anti-H. pylori activity.
The susceptibility of H. pylori isolates and strains to 543 extracts from 246 plant species was tested by disc diffusion, agar diffusion, agar dilution, and broth microdilution assays. Activity ranged from 1.56–100,000 µg/mL for minimal inhibitory concentration (MIC) and 7–42 mm for inhibition zone diameters (IZDs). However, disparities were observed among the methods used and the tested concentrations: some extracts were tested at very high concentrations (100,000 µg/mL) that might have resulted in biased conclusions. Though many plants (246 species) showed anti-H. pylori activity in vitro, very few have been screened for activity in animal models.
Organic extracts of Carum carvi, Xanthium brasilicum, and Trachyspermum copticum have demonstrated antibacterial activity against 10 clinical isolates of H. pylori []. In addition, ethanolic extracts of Cuminum cyminum and propolis exhibited significant in vitro inhibitory effect against H. pylori and, therefore, could be considered a valuable support in the treatment of infection, even contributing to the development of new and safer agents for inclusion in anti-H. pylori therapy regimens []. Some popular plant species used in Brazilian cuisine and folk medicine in the treatment of gastrointestinal disorders were also investigated for their antibacterial effects, among which Bixa orellana, Chamomilla recutita, Ilex paraguariensis, and Malva sylvestris were the most effective against H. pylori [].
Bioactive plant compounds were also tested for their anti-H. pylori potency (Table 10), namely those isolated from the Allium sativum (cloves), Convolvulus austro-aegyptiacu (aerial parts), Glycyrrhiza glabra (roots), Hydrastis canadensis (rhizomes), Sanguinaria canadensis (rhizomes), and Tinospora sagittata (aerial parts) species. Berberine, a benzylisoquinoline alkaloid, isolated from Hydrastis canadensis, revealed the lowest MIC value (0.78 μg/mL), being therefore considered the most effective bioactive compound, followed by diallyl tetrasulfide (3–6 μg/mL), allicin (4 μg/mL), and palmatine (3.12–6.25 μg/mL) isolated from Allium sativum and Tinospora sagittate, respectively.
Table 10.
Bioactive compounds with anti-H. pylori activity.
5. In Vivo Findings
H. pylori colonization is increasingly being associated with a heightened risk of developing upper gastrointestinal tract diseases. Despite many plant extracts having demonstrated a prominent H. pylori inhibition capacity in culture, it is of crucial importance to assess their in vivo efficacy, because it is pivotal to ascertain their effective antibacterial potency. However, a relatively low number of medicinal plants have been investigated to date for in vivo activity, as discussed below.
Paeonia lactiflora root extract (100 µg/mL) showed a complete inhibition of H. pylori colonization (4–5 × 105 colony forming unit (CFU)), being the antibacterial potential equivalent to of ampicillin used as positive control (10 µg/mL) (2–4 × 105 CFU) []. Time course viability experiments were also performed in simulated gastric environments to assess the anti-H. pylori activity of garlic (Allium sativum) oil (16 and 32 µg/mL). A rapid anti-H. pylori action in artificial gastric juice was found. Nevertheless, the anti-H. pylori activity displayed by garlic oil was noticeably affected by food materials and mucin, despite the fact that a substantial activity remained under simulated gastric conditions []. Also, H. pylori-inoculated Swiss mice receiving 125, 250, or 500 mg/kg of Bryophyllum pinnutum or ciprofloxacin (500 mg/kg) for 7 days, showed a significant reduction of H. pylori colonization on gastric tissue from 100% to 17%. In addition, the highest B. pinnatum extract tested (85.91 ± 52.91 CFU) and standard drug ciprofloxacin (25.74 ± 16.15 CFU) also reduced significantly (p < 0.05) the bacterial load of gastric mucosa as compared with untreated infected mice (11883 ± 1831 CFU) []. On the other hand, Eryngium foetidum methanol extract (381.9 ± 239.5 CFU) and positive control ciprofloxacin (248 ± 153.2 CFU) significantly reduced the bacterial load in gastric mucosa at the same dose (500 mg/kg) compared with untreated and inoculated mice (14350 ± 690 CFU) [].
Hippocratea celastroides hydroethanolic root-bark extract, a widely used plant against gastric and intestinal infections, also showed anti-H. pylori efficacy in naturally infected dogs. In a study of 18 experimental dogs treated with a dose of 93.5–500 mg/kg of H. celastroides extract in weight and 19 infected dogs receiving amoxicillin–clarithromycin–omeprazole (control treatment), the results showed effectiveness of 33.3 and 55% in the experimental and control groups, respectively [].
On the other hand, Ye et al. [], aiming to investigate the in vivo bactericidal effects of Chenopodium ambrosioides L. against H. pylori, randomly assigned H. pylori-infected mice into plant extract group, triple therapy control (lansoprazole, metronidazole, and clarithromycin), blank control, and H. pylori control groups. The obtained eradication ratios, determined by rapid urease tests (RUTs) and histopathology, were, respectively, 60% (6/10) using RUT and 50% (5/10) using histopathology for the test group and both 70% (7/10) for the control group. In addition, the histopathologic evaluation revealed a massive bacterial colonization on the gastric mucosa surface and slight mononuclear cells infiltration after H. pylori inoculation, but no obvious inflammation or other pathologic changes in gastric mucosa were stated between the C. ambrosioides-treated mice and the standard therapy.
Tinospora sagittata and its main component, palmatine, showed in vitro bactericidal effects on H pylori strains, with both MIC and minimal bactericidal concentration (MBC) values of 6250 μg/mL, whereas palmatine’s MIC value against H. pylori SCYA201401 was 6.25 μg/mL and against H. pylori SS1 was 3.12 μg/mL. The time-kill kinetic study evidenced a dose-dependent and progressive decline in the numbers of viable bacteria up to 40 h. H. pylori-infected mice treated with extract, palmatine, or control therapy (omeprazole, clarithromycin, and amoxicillin), presented eradication ratios of, respectively, 80%, 50%, and 70%. The anti-H. pylori activity found in T. sagittata extracts and its major constituent, palmatine, both in culture and animal models, clearly highlights the antibacterial potential of this plant in the treatment of both infected humans and animals [].
Total alkaloids fraction activity (TASA) of Sophora alopecuroides L., widely used in herbal remedies against stomach-associated diseases, were also investigated on 120 H. pylori-infected BALB/c mice mouse gastritis. A total of 100 infected mice were randomly assigned into 10 treatment groups: group I (normal saline); group II (bismuth pectin); group III (omeprazole); group IV (TASA 2 mg/day); group V (TASA 4 mg/day); group VI (TASA 5 mg/day); group VII (TASA + bismuth pectin); group VIII (TASA + omeprazole); group IX (bismuth pectin + clarithromycin + metronidazole); and group X (omeprazole + clarithromycin + metronidazole). The mice were sacrificed 4 weeks after treatment. Real-time PCR was used to detect 16sDNA of H. pylori to test both the colonization and mice clearance of bacteria of each treatment. Hematoxylin and eosin staining and immunostaining of mice gastric mucosa were also used to observe the general inflammation and related factors: IL-8, COX2, and nuclear factor-kappa B (NF-κB) expression changed after treatments. TASA combined with omeprazole or bismuth pectin showed promising antimicrobial activity against H. pylori, as well as conventional triple therapy. Indeed, hematoxylin and eosin staining and immune-staining of mice gastric mucosa evidenced that the inflammation on mice gastric mucosal membrane were also clearly relieved in TASA combined treatments and conventional triple therapy compared with normal saline-treated mice. Accordingly, from immunohistochemistry results, H. pylori-induced IL-8, COX2, and NF-κB were consistently suppressed in the seventh, eighth, ninth, and tenth groups to a certain extent [].
Pastene et al. [] investigated the inhibitory effects of a standardized apple peel polyphenol-rich extract (Malus pumila Mill., cited as Malus domestica) against H. pylori infection and vacuolating bacterial toxin (VacA)-induced vacuolation and found that the preparation significantly prevented vacuolation in HeLa cells with an IC50 value of 390 μg gallic acid equivalents (GAE)/mL and an in vitro anti-adhesive effect against H. pylori. A significant inhibition was also stated with 20–60% reduction of H. pylori attachment at concentrations between 0.250 and 5 mg GAE/mL. In a short-term infection model (C57BL6/J mice), doses of 150 and 300 mg/kg/day showed an inhibitory effect on H. pylori attachment. Orally administered apple peel polyphenols also showed an anti-inflammatory effect on H. pylori-associated gastritis, lowering malondialdehyde levels and gastritis scores.
Kim et al. [] investigated the GutGard™ ability (a flavonoid rich, Glycyrrhiza glabra root extract) to inhibit H. pylori growth both in Mongolian gerbils and C57BL/6 mouse models. Infected male Mongolian gerbils were orally treated once daily 6 times/week for 8 weeks with 15, 30, and 60 mg/kg GutGard™. Bacterial identification in the biopsy samples of gastric mucosa, via urease, catalase, and ELISA, as well as immunohistochemistry revealed a dose-dependent inhibition of H. pylori colonization in gastric mucosa by GutGard™. As well, the administration of 25 mg/kg GutGard™ in H. pylori-infected C57BL/6 mice significantly reduced H. pylori colonization in gastric mucosa, suggesting its usefulness in H. pylori infection prevention.
Calophyllum brasiliense stem bark preparations are popular remedies for the treatment of chronic ulcers. A current report evidenced gastroprotective, gastric acid inhibitory properties and anti-H. pylori activity in culture (MIC = 31 µg/mL) []. Hydroethanolic (50, 100, and 200 mg/kg) and dichloromethane (100 and 200 mg/kg) fractions-treated Wistar rats ulcerated by acetic acid and inoculated with H. pylori, showed a marked delay in ulcer healing and reduced the ulcerated area in a dose-dependent manner []. While the dichloromethane fraction, at 200 mg/kg, increased PGE2 levels, both the hydroethanolic and dichloromethane fractions decreased the number of urease-positive animals, as confirmed by the reduction of the H. pylori presence in histopathological analysis. This aspect suggests that the antiulcer activity of C. brasiliense is partly linked with its anti-H. pylori efficacy []. Also, phenolic-rich oregano (Origanum vulgare) and cranberry (Vaccinium macrocarpon) extracts showed a prominent ability to inhibit H. pylori through urease inhibition and disruption of energy production by inhibition of proline dehydrogenase at the plasma membrane [].
6. Urease Inhibition
The current therapies are challenged by the considerable number of emerging H. pylori-resistant strains. This fact has driven the need for alternative anti-H. pylori therapies that ideally should have good stability and low toxicity and to be able to inhibit urease activity []. It has been shown that H. pylori urease activity is crucial in bacterial survival and pathogenesis [].
The inhibitory potency of some anti-H. pylori medicinal plants has been reported [] and even investigated by some authors in the involved mechanisms of antibacterial action of those plant products [].
Table 11 briefly shows the studied plant extracts with prominent anti-urease activity. Amin et al. [] demonstrated that the methanolic and acetone extracts of some medicinal plants were able to inhibit urease activity. In fact, Acacia nilotica flower methanol and acetone extracts evidenced anti-H. pylori activity, being MIC values of 8–64 μg/mL and 4–64 μg/mL, respectively. Both extracts inhibited urease activity at 8.2–88.2% and 9.2–86.6%. Calotropis procera leaf and flower methanol and acetone extracts, with MIC values of 16–256 μg/mL, 32–256 μg/mL, and 8–128 μg/mL also displayed urease inhibitory effects, being, respectively, 12.2–48.2% and 7.2–58.2% for leaf and 9.3–68.2% for flower acetone extracts []. While A. nilotica extract exerted a competitive inhibition, that of C. procera extract displayed a mixed type of inhibition []. In addition, Casuarina equisetifolia fruit methanol extract, with MIC values varying from 128–512 μg/mL, also displayed 12.2–86.2% inhibition of urease activity [].
Table 11.
Urease inhibitory potential of plant extracts.
In another study, Camellia sinensis young non-fermented and semi-fermented shoot extracts, presented inhibition zone diameter (IZD) and MBC of, respectively, 22.5 mm at 20–60 μg/disk and 4 mg/mL, and 18 mm at 20–60 μg/disk and 5.5 mg/mL. They both inhibited Ure A and Ure B subunits production at 2.5 and 3.5 mg/mL []. Also, the Chamomilla recutita flower extract, which inhibited H. pylori growth at an MIC90 value of 125 mg/mL and a MIC50 value of 62.5 mg/mL, was able to inhibit the urease production []. In the same line, the methanol fraction of Euphorbia umbellata bark extract inhibited both H. pylori growth (44.6% inhibition) at 256 μg/mL and urease activity (78.6% inhibition) at 1024 μg/mL []. Moreover, the Peumus boldus flower aqueous extract showed anti-adherent activity against H. pylori and inhibited urease activity with an IC50 value of 23.4 μg GAE/mL []. The aqueous extract of Teminalia chebula fruit showed activity with MIC and MBC values of 125 mg/mL and 150 mg/mL, respectively, and inhibited H. pylori urease activity at a concentration of 1–2.5 mg/mL [].
7. Conclusions and Future Perspectives
Overall, the report suggests that the studied plant extracts possess anti-H. pylori activity, strengthening the claims made by traditional medicine practitioners about their putative anti-ulcerative properties. However, very few of them were investigated for efficacy in animal models or the ability to inhibit urease activity. Further studies are warranted for efficacy studies in animal models, elucidation of effective modes of action (including urease inhibition), and clinical trials in human being.
Author Contributions
All authors contributed equally to this work. B.S., J.S.-R., P.V.T.F., and N.M. critically reviewed the manuscript. All the authors read and approved the final manuscript.
Funding
The APC was funded by N Martins.
Acknowledgments
N. Martins would like to thank the Portuguese Foundation for Science and Technology (FCT–Portugal) for the Strategic project ref. UID/BIM/04293/2013 and “NORTE2020—Programa Operacional Regional do Norte” (NORTE-01-0145-FEDER-000012).
Conflicts of Interest
The authors declare no conflict of interest.
References
- Sharifi-Rad, M.; Nazaruk, J.; Polito, L.; Morais-Braga, M.F.B.; Rocha, J.E.; Coutinho, H.D.M.; Salehi, B.; Tabanelli, G.; Montanari, C.; del Mar Contreras, M.; et al. Matricaria genus as a source of antimicrobial agents: From farm to pharmacy and food applications. Microbiol. Res. 2018, 215, 76–88. [Google Scholar] [CrossRef]
- Sharifi-Rad, M.; Roberts, T.H.; Matthews, K.R.; Bezerra, C.F.; Morais-Braga, M.F.B.; Coutinho, H.D.M.; Sharopov, F.; Salehi, B.; Yousaf, Z.; Sharifi-Rad, M.; et al. Ethnobotany of the genus Taraxacum–Phytochemicals and antimicrobial activity. Phytother. Res. 2018. [Google Scholar] [CrossRef] [PubMed]
- Salehi, B.; Zucca, P.; Sharifi-Rad, M.; Pezzani, R.; Rajabi, S.; Setzer, W.N.; Varoni, E.M.; Iriti, M.; Kobarfard, F.; Sharifi-Rad, J. Phytotherapeutics in cancer invasion and metastasis. Phytother. Res. 2018, 32, 1425–1449. [Google Scholar] [CrossRef] [PubMed]
- Sharifi-Rad, J.; Iriti, M.; Setzer, W.N.; Sharifi-Rad, M.; Roointan, A.; Salehi, B. Antiviral activity of Veronica persica Poir. on herpes virus infection. Cell. Mol. Biol. (Noisy-le-Grand France) 2018, 64, 11–17. [Google Scholar] [CrossRef]
- Mishra, A.P.; Saklani, S.; Salehi, B.; Parcha, V.; Sharifi-Rad, M.; Milella, L.; Iriti, M.; Sharifi-Rad, J.; Srivastava, M. Satyrium nepalense, a high altitude medicinal orchid of Indian Himalayan region: Chemical profile and biological activities of tuber extracts. Cell. Mol. Biol. (Noisy-le-Grand France) 2018, 64, 35–43. [Google Scholar] [CrossRef]
- Mishra, A.P.; Sharifi-Rad, M.; Shariati, M.A.; Mabkhot, Y.N.; Al-Showiman, S.S.; Rauf, A.; Salehi, B.; Župunski, M.; Sharifi-Rad, M.; Gusain, P.; et al. Bioactive compounds and health benefits of edible Rumex species-A review. Cell. Mol. Biol. (Noisy-le-Grand France) 2018, 64, 27–34. [Google Scholar] [CrossRef]
- Monjazeb Marvdashti, L.; Abdolshahi, A.; Hedayati, S.; Sharifi-Rad, M.; Iriti, M.; Salehi, B.; Sharifi-Rad, J. Pullulan gum production from low-quality fig syrup using Aureobasidium pullulans. Cell. Mol. Biol. (Noisy-le-Grand France) 2018, 64, 22–26. [Google Scholar] [CrossRef]
- Salehi, B.; Anil Kumar, N.V.; Şener, B.; Sharifi-Rad, M.; Kılıç, M.; Mahady, G.B.; Vlaisavljevic, S.; Iriti, M.; Kobarfard, F.; Setzer, W.N.; et al. Medicinal plants used in the treatment of human immunodeficiency virus. Int. J. Mol. Sci. 2018, 19, 1459. [Google Scholar] [CrossRef] [PubMed]
- Bagheri, G.; Mirzaei, M.; Mehrabi, R.; Sharifi-Rad, J. Cytotoxic and antioxidant activities of Alstonia scholaris, Alstonia venenata and Moringa oleifera plants from India. Jundishapur J. Nat. Pharm. Prod. 2016, 11, e31129. [Google Scholar] [CrossRef]
- Sharifi-Rad, M.; Salehi, B.; Sharifi-Rad, J.; Setzer, W.N.; Iriti, M. Pulicaria vulgaris Gaertn. essential oil: An alternative or complementary treatment for Leishmaniasis. Cell. Mol. Biol. (Noisy-le-Grand France) 2018, 64, 18–21. [Google Scholar] [CrossRef]
- Sharifi-Rad, J.; Tayeboon, G.S.; Niknam, F.; Sharifi-Rad, M.; Mohajeri, M.; Salehi, B.; Iriti, M.; Sharifi-Rad, M. Veronica persica Poir. extract-antibacterial, antifungal and scolicidal activities, and inhibitory potential on acetylcholinesterase, tyrosinase, lipoxygenase and xanthine oxidase. Cell. Mol. Biol. (Noisy-le-Grand France) 2018, 64, 50–56. [Google Scholar] [CrossRef]
- Sharifi-Rad, J.; Sharifi-Rad, M.; Salehi, B.; Iriti, M.; Roointan, A.; Mnayer, D.; Soltani-Nejad, A.; Afshari, A. In vitro and in vivo assessment of free radical scavenging and antioxidant activities of Veronica persica Poir. Cell. Mol. Biol. (Noisy-le-Grand France) 2018, 64, 57–64. [Google Scholar] [CrossRef]
- Martins, N.; Barros, L.; Ferreira, I.C. In vivo antioxidant activity of phenolic compounds: Facts and gaps. Trends Food Sci. Technol. 2016, 48, 1–12. [Google Scholar] [CrossRef]
- Sharifi-Rad, J.; Ayatollahi, S.A.; Varoni, E.M.; Salehi, B.; Kobarfard, F.; Sharifi-Rad, M.; Iriti, M.; Sharifi-Rad, M. Chemical composition and functional properties of essential oils from Nepeta schiraziana Boiss. Farmacia 2017, 65, 802–812. [Google Scholar]
- Salehi, B.; Mishra, A.P.; Shukla, I.; Sharifi-Rad, M.; Contreras, M.d.M.; Segura-Carretero, A.; Fathi, H.; Nasrabadi, N.N.; Kobarfard, F.; Sharifi-Rad, J. Thymol, thyme, and other plant sources: Health and potential uses. Phytother. Res. 2018. [Google Scholar] [CrossRef] [PubMed]
- Sharifi-Rad, M.; Varoni, E.M.; Iriti, M.; Martorell, M.; Setzer, W.N.; del Mar Contreras, M.; Salehi, B.; Soltani-Nejad, A.; Rajabi, S.; Tajbakhsh, M.; et al. Carvacrol and human health: A comprehensive review. Phytother. Res. 2018. [Google Scholar] [CrossRef] [PubMed]
- Martins, N.; Barros, L.; Henriques, M.; Silva, S.; Ferreira, I.C. In vivo anti-candida activity of phenolic extracts and compounds: Future perspectives focusing on effective clinical interventions. BioMed Res. Int. 2015, 2015, 247382. [Google Scholar] [CrossRef] [PubMed]
- Sharifi-Rad, M.; Mnayer, D.; Morais-Braga, M.F.B.; Carneiro, J.N.P.; Bezerra, C.F.; Coutinho, H.D.M.; Salehi, B.; Martorell, M.; del Mar Contreras, M.; Soltani-Nejad, A.; et al. Echinacea plants as antioxidant and antibacterial agents: From traditional medicine to biotechnological applications. Phytother. Res. 2018. [Google Scholar] [CrossRef] [PubMed]
- Snow Setzer, M.; Sharifi-Rad, J.; Setzer, W.N. The search for herbal antibiotics: An in-silico investigation of antibacterial phytochemicals. Antibiotics 2016, 5, 30. [Google Scholar] [CrossRef] [PubMed]
- Sharifi-Rad, J.; Mnayer, D.; Roointan, A.; Shahri, F.; Ayatollahi, S.; Sharifi-Rad, M.; Molaee, N. Antibacterial activities of essential oils from Iranian medicinal plants on extended-spectrum β-lactamase-producing Escherichia coli. Cell. Mol. Biol. 2016, 62, 75–82. [Google Scholar] [PubMed]
- Sharifi-Rad, M.; Iriti, M.; Gibbons, S.; Sharifi-Rad, J. Anti-methicillin-resistant Staphylococcus aureus (MRSA) activity of Rubiaceae, Fabaceae and Poaceae plants: A search for new sources of useful alternative antibacterials against MRSA infections. Cell. Mol. Biol. 2016, 62, 39–45. [Google Scholar] [PubMed]
- Sharifi-Rad, J.; Salehi, B.; Varoni, E.M.; Sharopov, F.; Yousaf, Z.; Ayatollahi, S.A.; Kobarfard, F.; Sharifi-Rad, M.; Afdjei, M.H.; Sharifi-Rad, M.; et al. Plants of the Melaleuca Genus as Antimicrobial Agents: From Farm to Pharmacy. Phytother. Res. 2017, 31, 1475–1494. [Google Scholar] [CrossRef] [PubMed]
- Sharifi-Rad, M.; Varoni, E.M.; Salehi, B.; Sharifi-Rad, J.; Matthews, K.R.; Ayatollahi, S.A.; Kobarfard, F.; Ibrahim, S.A.; Mnayer, D.; Zakaria, Z.A.; et al. Plants of the genus Zingiber as a source of bioactive phytochemicals: From tradition to pharmacy. Molecules 2017, 22, 2145. [Google Scholar] [CrossRef] [PubMed]
- Sharifi-Rad, J.; Salehi, B.; Schnitzler, P.; Ayatollahi, S.A.; Kobarfard, F.; Fathi, M.; Eisazadeh, M.; Sharifi-Rad, M. Susceptibility of herpes simplex virus type 1 to monoterpenes thymol, carvacrol, p-cymene and essential oils of Sinapis arvensis L., Lallemantia royleana Benth. and Pulicaria vulgaris Gaertn. Cell. Mol. Biol. 2017, 63, 42–47. [Google Scholar] [CrossRef] [PubMed]
- Sharifi-Rad, J.; Salehi, B.; Stojanović-Radić, Z.Z.; Fokou, P.V.T.; Sharifi-Rad, M.; Mahady, G.B.; Sharifi-Rad, M.; Masjedi, M.R.; Lawal, T.O.; Ayatollahi, S.A.; et al. Medicinal plants used in the treatment of tuberculosis—Ethnobotanical and ethnopharmacological approaches. Biotechnol. Adv. 2017. [Google Scholar] [CrossRef] [PubMed]
- Salehi, B.; Ayatollahi, S.A.; Segura-Carretero, A.; Kobarfard, F.; Contreras, M.D.M.; Faizi, M.; Sharifi-Rad, M.; Tabatabai, S.A.; Sharifi-Rad, J. Bioactive chemical compounds in Eremurus persicus (Joub. & Spach) Boiss. essential oil and their health implications. Cell. Mol. Biol. 2017, 63, 1–7. [Google Scholar] [PubMed]
- Abdolshahi, A.; Naybandi-Atashi, S.; Heydari-Majd, M.; Salehi, B.; Kobarfard, F.; Ayatollahi, S.A.; Ata, A.; Tabanelli, G.; Sharifi-Rad, M.; Montanari, C.; et al. Antibacterial activity of some Lamiaceae species against Staphylococcus aureus in yoghurt-based drink (Doogh). Cell. Mol. Biol. (Noisy-le-Grand France) 2018, 64, 71–77. [Google Scholar] [CrossRef]
- Sharifi-Rad, J.; Roointan, A.; Setzer, W.N.; Sharifi-Rad, M.; Iriti, M.; Salehi, B. Susceptibility of Leishmania major to Veronica persica Poir. extracts-In vitro and in vivo assays. Cell. Mol. Biol. (Noisy-le-Grand France) 2018, 64, 44–49. [Google Scholar] [CrossRef]
- Percival, S.L.; Suleman, L. Biofilms and Helicobacter pylori: Dissemination and persistence within the environment and host. World J. Gastrointest. Pathophysiol. 2014, 5, 122. [Google Scholar] [CrossRef] [PubMed]
- Modolo, L.V.; de Souza, A.X.; Horta, L.P.; Araujo, D.P.; de Fátima, Â. An overview on the potential of natural products as ureases inhibitors: A review. J. Adv. Res. 2015, 6, 35–44. [Google Scholar] [CrossRef] [PubMed]
- Zhang, X.-Y.; Zhang, P.-Y.; Aboul-Soud, M.A. From inflammation to gastric cancer: Role of Helicobacter pylori. Oncol. Lett. 2017, 13, 543–548. [Google Scholar] [CrossRef] [PubMed]
- Sharifi-Rad, M.; Fokou, P.; Sharopov, F.; Martorell, M.; Ademiluyi, A.; Rajkovic, J.; Salehi, B.; Martins, N.; Iriti, M.; Sharifi-Rad, J. Antiulcer Agents: From Plant Extracts to Phytochemicals in Healing Promotion. Molecules 2018, 23, 1751. [Google Scholar] [CrossRef] [PubMed]
- Sipponen, P.; Marshall, B.J. Gastritis and gastric cancer: Western countries. Gastroenterol. Clin. N. Am. 2000, 29, 579–592. [Google Scholar] [CrossRef]
- Park, J.Y.; Forman, D.; Waskito, L.A.; Yamaoka, Y.; Crabtree, J.E. Epidemiology of Helicobacter pylori and CagA-Positive Infections and Global Variations in Gastric Cancer. Toxins 2018, 10, 163. [Google Scholar] [CrossRef] [PubMed]
- Nagy, T.A.; Frey, M.R.; Yan, F.; Israel, D.A.; Polk, D.B.; Peek, R.M. Helicobacter pylori regulates cellular migration and apoptosis by activation of phosphatidylinositol 3-kinase signaling. J. Infect. Dis. 2009, 199, 641–651. [Google Scholar] [CrossRef] [PubMed]
- Wroblewski, L.E.; Peek, R.M.; Wilson, K.T. Helicobacter pylori and gastric cancer: Factors that modulate disease risk. Clin. Microbiol. Rev. 2010, 23, 713–739. [Google Scholar] [CrossRef] [PubMed]
- Tsugane, S. Salt, salted food intake, and risk of gastric cancer: Epidemiologic evidence. Cancer Sci. 2005, 96, 1–6. [Google Scholar] [CrossRef] [PubMed]
- Gisbert, J.; Gonzalez, L.; Calvet, X.; García, N.; López, T.; Roque, M.; Gabriel, R.; Pajares, J. Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: A meta-analysis of eradication of Helicobacter pylori. Aliment. Pharmacol. Ther. 2000, 14, 1319–1328. [Google Scholar] [CrossRef] [PubMed]
- Molina-Infante, J.; Gisbert, J.P. Optimizing clarithromycin-containing therapy for Helicobacter pylori in the era of antibiotic resistance. World J. Gastroenterol. 2014, 20, 10338–10347. [Google Scholar] [CrossRef] [PubMed]
- Hsu, P.-I.; Wu, D.-C.; Chen, W.-C.; Tseng, H.-H.; Yu, H.-C.; Wang, H.-M.; Kao, S.-S.; Lai, K.-H.; Chen, A.; Tsay, F.-W. Randomized controlled trial comparing 7-day triple, 10-day sequential, and 7-day concomitant therapies for Helicobacter pylori infection. Antimicrob. Agents Chemother. 2014, 58, 5936–5942. [Google Scholar] [CrossRef] [PubMed]
- Malfertheiner, P.; Megraud, F.; O’Morain, C.A.; Gisbert, J.P.; Kuipers, E.J.; Axon, A.T.; Bazzoli, F.; Gasbarrini, A.; Atherton, J.; Graham, D.Y.; et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 2017, 66, 6–30. [Google Scholar] [CrossRef] [PubMed]
- Rong, Q.; Xu, M.; Dong, Q.; Zhang, Y.; Li, Y.; Ye, G.; Zhao, L. In vitro and in vivo bactericidal activity of Tinospora sagittata (Oliv.) Gagnep. var. craveniana (S.Y.Hu) Lo and its main effective component, palmatine, against porcine Helicobacter pylori. BMC Complement. Altern. Med. 2016, 16, 331. [Google Scholar] [CrossRef] [PubMed]
- Lansdorp-Vogelaar, I.; Sharp, L. Cost-effectiveness of screening and treating Helicobacter pylori for gastric cancer prevention. Best Pract. Res. Clin. Gastroenterol. 2013, 27, 933–947. [Google Scholar] [CrossRef] [PubMed]
- Wang, Y.C. Medicinal plant activity on Helicobacter pylori related diseases. World J. Gastroenterol. 2014, 20, 10368–10382. [Google Scholar] [CrossRef] [PubMed]
- Vale, F.F.; Oleastro, M. Overview of the phytomedicine approaches against Helicobacter pylori. World J. Gastroenterol. 2014, 20, 5594–5609. [Google Scholar] [CrossRef] [PubMed]
- Nariman, F.; Eftekhar, F.; Habibi, Z.; Massarrat, S.; Malekzadeh, R. Antibacterial activity of twenty Iranian plant extracts against clinical isolates of Helicobacter pylori. Iran. J. Basic Med. Sci. 2009, 12, 105–111. [Google Scholar]
- Nostro, A.; Cellini, L.; Bartolomeo, S.D.; Campli, E.D.; Grande, R.; Cannatelli, M.; Marzio, L.; Alonzo, V. Antibacterial effect of plant extracts against Helicobacter pylori. Phytother. Res. 2005, 19, 198–202. [Google Scholar] [CrossRef] [PubMed]
- Cogo, L.L.; Monteiro, C.L.B.; Miguel, M.D.; Miguel, O.G.; Cunico, M.M.; Ribeiro, M.L.; de Camargo, E.R.; Kussen, G.M.B.; Nogueira, K.d.S.; Costa, L.M.D. Anti-Helicobacter pylori activity of plant extracts traditionally used for the treatment of gastrointestinal disorders. Braz. J. Microbiol. 2010, 41, 304–309. [Google Scholar] [CrossRef] [PubMed]
- Amin, M.; Anwar, F.; Naz, F.; Mehmood, T.; Saari, N. Anti-Helicobacter pylori and urease inhibition activities of some traditional medicinal plants. Molecules 2013, 18, 2135–2149. [Google Scholar] [CrossRef] [PubMed]
- Njume, C.; Afolayan, A.J.; Samie, A.; Ndip, R.N. Inhibitory and Bactericidal Potential of Crude Acetone Extracts of Combretum molle (Combretaceae) on Drug-resistant Strains of Helicobacter pylori. J. Health Popul. Nutr. 2011, 29, 438–445. [Google Scholar] [CrossRef]
- Njume, C.; Jide, A.A.; Ndip, R.N. Aqueous and Organic Solvent-Extracts of Selected South African Medicinal Plants Possess Antimicrobial Activity against Drug-Resistant Strains of Helicobacter pylori: Inhibitory and Bactericidal Potential. Int. J. Mol. Sci. 2011, 12, 5652–5665. [Google Scholar] [CrossRef] [PubMed]
- Castillo-Juarez, I.; Gonzalez, V.; Jaime-Aguilar, H.; Martinez, G.; Linares, E.; Bye, R.; Romero, I. Anti-Helicobacter pylori activity of plants used in Mexican traditional medicine for gastrointestinal disorders. J. Ethnopharmacol. 2009, 122, 402–405. [Google Scholar] [CrossRef] [PubMed]
- Okeleye, B.I.; Bessong, P.O.; Ndip, R.N. Preliminary phytochemical screening and in vitro anti-Helicobacter pylori activity of extracts of the stem bark of Bridelia micrantha (Hochst., Baill., Euphorbiaceae). Molecules 2011, 16, 6193–6205. [Google Scholar] [CrossRef] [PubMed]
- Yesilada, E.; Gurbuz, I.; Shibata, H. Screening of Turkish anti-ulcerogenic folk remedies for anti-Helicobacter pylori activity. J. Ethnopharmacol. 1999, 66, 289–293. [Google Scholar] [CrossRef]
- Li, Y.; Xu, C.; Zhang, Q.; Liu, J.Y.; Tan, R.X. In vitro anti-Helicobacter pylori action of 30 Chinese herbal medicines used to treat ulcer diseases. J. Ethnopharmacol. 2005, 98, 329–333. [Google Scholar] [CrossRef] [PubMed]
- Poovendran, P.; Kalaigandhi, V.; Poongunran, E. Antimicrobial activity of the leaves of Cocculus hirsutus against gastric ulcer producing Helicobacter pylori. J. Pharm. Res. 2011, 4, 4294–4295. [Google Scholar]
- Palacios-Espinosa, J.F.; Arroyo-Garcia, O.; Garcia-Valencia, G.; Linares, E.; Bye, R.; Romero, I. Evidence of the anti-Helicobacter pylori, gastroprotective and anti-inflammatory activities of Cuphea aequipetala infusion. J. Ethnopharmacol. 2014, 151, 990–998. [Google Scholar] [CrossRef] [PubMed]
- Escobedo-Hinojosa, W.I.; Del Carpio, J.D.; Palacios-Espinosa, J.F.; Romero, I. Contribution to the ethnopharmacological and anti-Helicobacter pylori knowledge of Cyrtocarpa procera Kunth (Anacardiaceae). J. Ethnopharmacol. 2012, 143, 363–371. [Google Scholar] [CrossRef] [PubMed]
- Uyub, A.M.; Nwachukwu, I.N.; Azlan, A.A.; Fariza, S.S. In-vitro antibacterial activity and cytotoxicity of selected medicinal plant extracts from Penang Island Malaysia on metronidazole-resistant-Helicobacter pylori and some pathogenic bacteria. Ethnobot. Res. Appl. 2010, 8, 095–106. [Google Scholar] [CrossRef]
- Shahani, S.; Monsef-Esfahani, H.R.; Saeidnia, S.; Saniee, P.; Siavoshi, F.; Foroumadi, A.; Samadi, N.; Gohari, A.R. Anti-Helicobacter pylori activity of the methanolic extract of Geum iranicum and its main compounds. Z. Naturforsch. C J. Biosci. 2012, 67, 172–180. [Google Scholar] [CrossRef]
- Pastene, E.; Parada, V.; Avello, M.; Ruiz, A.; Garcia, A. Catechin-based procyanidins from Peumus boldus Mol. aqueous extract inhibit Helicobacter pylori urease and adherence to adenocarcinoma gastric cells. Phytother. Res. 2014, 28, 1637–1645. [Google Scholar] [CrossRef] [PubMed]
- Pinheiro Silva, L.; Damacena de Angelis, C.; Bonamin, F.; Kushima, H.; José Mininel, F.; Campaner dos Santos, L.; Karina Delella, F.; Luis Felisbino, S.; Vilegas, W.; Regina Machado da Rocha, L.; et al. Terminalia catappa L.: A medicinal plant from the Caribbean pharmacopeia with anti-Helicobacter pylori and antiulcer action in experimental rodent models. J. Ethnopharmacol. 2015, 159, 285–295. [Google Scholar] [CrossRef] [PubMed]
- Malekzadeh, F.; Ehsanifar, H.; Shahamat, M.; Levin, M.; Colwell, R.R. Antibacterial activity of black myrobalan (Terminalia chebula Retz) against Helicobacter pylori. Int. J. Antimicrob. Agents 2001, 18, 85–88. [Google Scholar] [CrossRef]
- Bergonzelli, G.E.; Donnicola, D.; Porta, N.; Corthésy-Theulaz, I.E. Essential Oils as Components of a Diet-Based Approach to Management of Helicobacter Infection. Antimicrob. Agents Chemother. 2003, 47, 3240–3246. [Google Scholar] [CrossRef] [PubMed]
- O’Gara, E.A.; Maslin, D.J.; Nevill, A.M.; Hill, D.J. The effect of simulated gastric environments on the anti-Helicobacter activity of garlic oil. J. Appl. Microbiol. 2008, 104, 1324–1331. [Google Scholar] [CrossRef] [PubMed]
- Hosseininejad, Z.; Moghadam, S.D.; Ebrahimi, F.; Abdollahi, M.; Zahedi, M.J.; Nazari, M.; Hayatbakhsh, M.; Adeli, S.; Sharififar, F. In vitro screening of selected Iranian medicinal plants against Helicobacter pylori. Int. J. Green Pharm. 2011, 5, 282–285. [Google Scholar]
- Awaad, A.S.; Al-Rifai, A.A.; El-Meligy, R.M.; Alafeefy, A.M.; Zain, M.E. New Activities for Isolated Compounds from Convolvulus austro-aegyptiacus as Anti-ulcerogenic, Anti-Helicobacter pylori and Their Mimic Synthesis Using Bio-guided Fractionation. Phytother. Res. 2015. [Google Scholar] [CrossRef] [PubMed]
- Ndip, R.N.; Malange Tarkang, A.E.; Mbullah, S.M.; Luma, H.N.; Malongue, A.; Ndip, L.M.; Nyongbela, K.; Wirmum, C.; Efange, S.M. In vitro anti-Helicobacter pylori activity of extracts of selected medicinal plants from North West Cameroon. J. Ethnopharmacol. 2007, 114, 452–457. [Google Scholar] [CrossRef] [PubMed]
- Mahady, G.B.; Pendland, S.L.; Stoia, A.; Hamill, F.A.; Fabricant, D.; Dietz, B.M.; Chadwick, L.R. In vitro susceptibility of Helicobacter pylori to botanical extracts used traditionally for the treatment of gastrointestinal disorders. Phytother. Res. 2005, 19, 988–991. [Google Scholar] [CrossRef] [PubMed]
- Kouitcheu Mabeku, L.B.; Nanfack Nana, B.; Eyoum Bille, B.; Tchuenteu Tchuenguem, R.; Nguepi, E. Anti-Helicobacter pylori and antiulcerogenic activity of Aframomum pruinosum seeds on indomethacin-induced gastric ulcer in rats. Pharm. Biol. 2017, 55, 929–936. [Google Scholar] [CrossRef] [PubMed]
- Krivokuca, M.; Niketic, M.; Milenkovic, M.; Golic, N.; Masia, C.; Scaltrito, M.M.; Sisto, F.; Kundakovic, T. Anti-Helicobacter pylori Activity of Four Alchemilla Species (Rosaceae). Nat. Prod. Commun. 2015, 10, 1369–1371. [Google Scholar] [PubMed]
- Lima, Z.P.; Calvo, T.R.; Silva, E.F.; Pellizzon, C.H.; Vilegas, W.; Brito, A.R.; Bauab, T.M.; Hiruma-Lima, C.A. Brazilian medicinal plant acts on prostaglandin level and Helicobacter pylori. J. Med. Food 2008, 11, 701–708. [Google Scholar] [CrossRef] [PubMed]
- Kouitcheu Mabeku, L.B.; Eyoum Bille, B.; Nguepi, E. In Vitro and In Vivo Anti-Helicobacter Activities of Eryngium foetidum (Apiaceae), Bidens pilosa (Asteraceae), and Galinsoga ciliata (Asteraceae) against Helicobacter pylori. Biomed. Res. Int. 2016, 2016, 2171032. [Google Scholar] [CrossRef] [PubMed]
- Kouitcheu Mabeku, L.B.; Eyoum Bille, B.; Tchouangueu, T.F.; Nguepi, E.; Leundji, H. Treatment of Helicobacter pylori infected mice with Bryophyllum pinnatum, a medicinal plant with antioxidant and antimicrobial properties, reduces bacterial load. Pharm. Biol. 2017, 55, 603–610. [Google Scholar] [CrossRef] [PubMed]
- Souza Mdo, C.; Beserra, A.M.; Martins, D.C.; Real, V.V.; Santos, R.A.; Rao, V.S.; Silva, R.M.; Martins, D.T. In vitro and in vivo anti-Helicobacter pylori activity of Calophyllum brasiliense Camb. J. Ethnopharmacol. 2009, 123, 452–458. [Google Scholar] [CrossRef] [PubMed]
- Miguel, G.; Faleiro, L.; Cavaleiro, C.; Salgueiro, L.; Casanova, J. Susceptibility of Helicobacter pylori to essential oil of Dittrichia viscosa subsp. revoluta. Phytother. Res. 2008, 22, 259–263. [Google Scholar] [CrossRef] [PubMed]
- Minozzo, B.R.; Lemes, B.M.; Justo, A.D.S.; Lara, J.E.; Petry, V.E.K.; Fernandes, D.; Bello, C.; Vellosa, J.C.R.; Campagnoli, E.B.; Nunes, O.C.; et al. Anti-ulcer mechanisms of polyphenols extract of Euphorbia umbellata (Pax) Bruyns (Euphorbiaceae). J. Ethnopharmacol. 2016, 191, 29–40. [Google Scholar] [CrossRef] [PubMed]
- Fukai, T.; Marumo, A.; Kaitou, K.; Kanda, T.; Terada, S.; Nomura, T. Anti-Helicobacter pylori flavonoids from licorice extract. Life Sci. 2002, 71, 1449–1463. [Google Scholar] [CrossRef]
- Hinojosa, W.I.; Quiroz, M.A.; Alvarez, I.R.; Castaneda, P.E.; Villarreal, M.L.; Taketa, A.C. Anti-Helicobacter pylori, gastroprotective, anti-inflammatory, and cytotoxic activities of methanolic extracts of five different populations of Hippocratea celastroides collected in Mexico. J. Ethnopharmacol. 2014, 155, 1156–1163. [Google Scholar] [CrossRef] [PubMed]
- Mahady, G.B.; Pendland, S.L.; Stoia, A.; Chadwick, L.R. In vitro susceptibility of Helicobacter pylori to isoquinoline alkaloids from Sanguinaria canadensis and Hydrastis canadensis. Phytother. Res. 2003, 17, 217–221. [Google Scholar] [CrossRef] [PubMed]
- Garro, M.F.; Salinas Ibanez, A.G.; Vega, A.E.; Arismendi Sosa, A.C.; Pelzer, L.; Saad, J.R.; Maria, A.O. Gastroprotective effects and antimicrobial activity of Lithraea molleoides and isolated compounds against Helicobacter pylori. J. Ethnopharmacol. 2015, 176, 469–474. [Google Scholar] [CrossRef] [PubMed]
- Ngan, L.T.M.; Moon, J.-K.; Shibamoto, T.; Ahn, Y.-J. Growth-Inhibiting, Bactericidal, and Urease Inhibitory Effects of Paeonia lactiflora Root Constituents and Related Compounds on Antibiotic-Susceptible and -Resistant Strains of Helicobacter pylori. J. Agric. Food Chem. 2012, 60, 9062–9073. [Google Scholar] [CrossRef] [PubMed]
- Khanavi, M.; Safavi, S.M.; Siavashi, F.; Falah Tafti, A.; Haji Mahmoudi, M.; Haji Akhoundi, A.; Rezazadeh, S.A.; Foroumadi, A.R. Evaluation of anti-Helicobacter pylori activity of methanol extracts of some species of Stachys and Melia. J. Med. Plants 2008, 28, 74–80. [Google Scholar]
- Ramadan, M.A.; Safwat, N.A. Antihelicobacter Activity of a Flavonoid Compound Isolated from Desmostachya Bipinnata. Aust. J. Basic Appl. Sci. 2009, 3, 2270–2277. [Google Scholar]
- Stamatis, G.; Kyriazopoulos, P.; Golegou, S.; Basayiannis, A.; Skaltsas, S.; Skaltsa, H. In vitro anti-Helicobacter pylori activity of Greek herbal medicines. J. Ethnopharmacol. 2003, 88, 175–179. [Google Scholar] [CrossRef]
- Manayi, A.; Khanavi, M.; Saiednia, S.; Azizi, E.; Mahmoodpour, M.R.; Vafi, F.; Malmir, M.; Siavashi, F.; Hadjiakhoondi, A. Biological activity and microscopic characterization of Lythrum salicaria L. DARU J. Pharm. Sci. 2013, 21, 61. [Google Scholar] [CrossRef] [PubMed]
- Mafioleti, L.; da Silva Junior, I.F.; Colodel, E.M.; Flach, A.; Martins, D.T. Evaluation of the toxicity and antimicrobial activity of hydroethanolic extract of Arrabidaea chica (Humb. & Bonpl.) B. Verl. J. Ethnopharmacol. 2013, 150, 576–582. [Google Scholar] [PubMed]
- Moraes Tde, M.; Rodrigues, C.M.; Kushima, H.; Bauab, T.M.; Villegas, W.; Pellizzon, C.H.; Brito, A.R.; Hiruma-Lima, C.A. Hancornia speciosa: Indications of gastroprotective, healing and anti-Helicobacter pylori actions. J. Ethnopharmacol. 2008, 120, 161–168. [Google Scholar] [CrossRef] [PubMed]
- Nariman, F.; Eftekhar, F.; Habibi, Z.; Falsafi, T. Anti-Helicobacter pylori activities of six Iranian plants. Helicobacter 2004, 9, 146–151. [Google Scholar] [CrossRef] [PubMed]
- Zhang, X.Q.; Gu, H.M.; Li, X.Z.; Xu, Z.N.; Chen, Y.S.; Li, Y. Anti-Helicobacter pylori compounds from the ethanol extracts of Geranium wilfordii. J. Ethnopharmacol. 2013, 147, 204–207. [Google Scholar] [CrossRef] [PubMed]
- Wang, Y.; Wang, S.L.; Zhang, J.Y.; Song, X.N.; Zhang, Z.Y.; Li, J.F.; Li, S. Anti-ulcer and anti-Helicobacter pylori potentials of the ethyl acetate fraction of Physalis alkekengi L. var. franchetii (Solanaceae) in rodent. J. Ethnopharmacol. 2017, 211, 197–206. [Google Scholar] [CrossRef] [PubMed]
- Lemos, L.M.S.; Martins, T.B.; Tanajura, G.H.; Gazoni, V.F.; Bonaldo, J.; Strada, C.L.; Silva, M.G.D.; Dall’Oglio, E.L.; de Sousa Júnior, P.T.; Martins, D.T.D.O. Evaluation of antiulcer activity of chromanone fraction from Calophyllum brasiliesnse Camb. J. Ethnopharmacol. 2012, 141, 432–439. [Google Scholar] [CrossRef] [PubMed]
- Sidahmed, H.M.A.; Azizan, A.H.S.; Mohan, S.; Abdulla, M.A.; Abdelwahab, S.I.; Taha, M.M.E.; Hadi, A.H.A.; Ketuly, K.A.; Hashim, N.M.; Loke, M.F.; et al. Gastroprotective effect of desmosdumotin C isolated from Mitrella kentii against ethanol-induced gastric mucosal hemorrhage in rats: Possible involvement of glutathione, heat-shock protein-70, sulfhydryl compounds, nitric oxide, and anti-Helicobacter pylori activity. BMC Complement. Altern. Med. 2013, 13, 183. [Google Scholar] [PubMed]
- Hassani, A.R.; Ordouzadeh, N.; Ghaemi, A.; Amirmozafari, N.; Hamdi, K.; Nazari, R. In vitro inhibition of Helicobacter pylori urease with non and semi fermented Camellia sinensis. Indian J. Med. Microbiol. 2009, 27, 30–34. [Google Scholar] [PubMed]
- Ye, H.; Liu, Y.; Li, N.; Yu, J.; Cheng, H.; Li, J.; Zhang, X.-Z. Anti-Helicobacter pylori activities of Chenopodium ambrosioides L. in vitro and in vivo. World J. Gastroenterol. 2015, 21, 4178–4183. [Google Scholar] [CrossRef] [PubMed]
- O’Gara, E.A.; Hill, D.J.; Maslin, D.J. Activities of Garlic Oil, Garlic Powder, and Their Diallyl Constituents against Helicobacter pylori. Appl. Environ. Microbiol. 2000, 66, 2269–2273. [Google Scholar] [CrossRef] [PubMed]
- Nontakham, J.; Charoenram, N.; Upamai, W.; Taweechotipatr, M.; Suksamrarn, S. Anti-Helicobacter pylori xanthones of Garcinia fusca. Arch. Pharm. Res. 2014, 37, 972–977. [Google Scholar] [CrossRef] [PubMed]
- Jung, J.; Bae, K.H.; Jeong, C.-S. Anti-Helicobacter pylori and Antiulcerogenic Activities of the Root Cortex of Paeonia suffruticosa. Biol. Pharm. Bull. 2013, 36, 1535–1539. [Google Scholar] [CrossRef] [PubMed]
- Garcia-Alonso, G.; Monroy-Noyola, A.; Contreras-Arellano, A.; Mariscal-Durand, J.F.; Galvez-Molina, Y.; Vazquez-Velazquez, A.; Garcia-Jimenez, S.; Nunez, P.; Cardoso-Taketa, A.; Villarreal, M.L. Preclinical evaluation of anti-Helicobacter spp. activity of Hippocratea celastroides Kunth and its acute and sub-acute toxicity. BMC Complement. Altern. Med. 2016, 16, 445. [Google Scholar] [CrossRef] [PubMed]
- Tian, A.; Xu, T.; Liu, K.; Zou, Q.; Yan, X. Anti-Helicobacter pylori effect of total alkaloids of sophora alopecuroides in vivo. Chin. Med. J. 2014, 127, 2484–2491. [Google Scholar] [PubMed]
- Pastene, E.; Speisky, H.; García, A.; Moreno, J.; Troncoso, M.; Figueroa, G. In Vitro and in Vivo Effects of Apple Peel Polyphenols against Helicobacter pylori. J. Agric. Food Chem. 2010, 58, 7172–7179. [Google Scholar] [CrossRef] [PubMed]
- Kim, J.M.; Zheng, H.M.; Lee, B.Y.; Lee, W.K.; Lee, D.H. Anti-Helicobacter pylori Properties of GutGard. Prev. Nutr. Food Sci. 2013, 18, 104–110. [Google Scholar] [CrossRef] [PubMed]
- Lin, Y.; Kwon, Y.; Labbe, R.; Shetty, K. Inhibition of Helicobacter pylori and associated urease by oregano and cranberry phytochemical synergies. Appl. Environ. Microbiol. 2005, 71, 8558–8564. [Google Scholar] [CrossRef] [PubMed]
- Kuwahara, H.; Miyamoto, Y.; Akaike, T.; Kubota, T.; Sawa, T.; Okamoto, S.; Maeda, H. Helicobacter pylori Urease Suppresses Bactericidal Activity of Peroxynitrite via Carbon Dioxide Production. Infect. Immun. 2000, 68, 4378–4383. [Google Scholar] [CrossRef] [PubMed]
- Shikov, A.N.; Pozharitskaya, O.N.; Makarov, V.G.; Kvetnaya, A.S. Antibacterial activity of Chamomilla recutita oil extract against Helicobacter pylori. Phytother. Res. 2008, 22, 252–253. [Google Scholar] [CrossRef] [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).